Profitelligence Profitelligence · Filing Ledger Open JNJ research →

Form 8-K · Current Report · Filed 2024-08-26

Johnson & Johnson Announces Retirement of Chief Human Resources Officer

Johnson & Johnson announced on August 26, 2024, that Peter M.

Filer
Johnson & Johnson JNJ · NYSE
Filed
Accession
0000200406-24-000079
CIK
0000200406
Signal
High impactHealthcare

Details

Fasolo, Executive Vice President and Chief Human Resources Officer (CHRO), will retire at the end of the year. Kristen Mulholland will succeed Fasolo as CHRO, effective October 1, 2024. Fasolo, who has been with the company for 16 years, has been instrumental in shaping the company's human capital strategy and will work with Mulholland during the transition period.

Items reported

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

CEO Resignation

Market reaction

Close before filing

$164.13

Next session

-0.7%

Since filing

+56.2%

Latest close

$256.35

What happened, not what will happen — closing prices around the filing date.

Exhibits (1)

About Johnson & Johnson

Johnson & Johnson is a multinational corporation engaged in the research, development, production, and sale of a broad range of healthcare products. Primarily known for its pharmaceuticals, medical devices, and consumer health products, Johnson & Johnson has a significant presence in the global healthcare industry. It develops medications for a variety of fields such as immunology, oncology, neurology, infectious diseases, and vaccines. The company also produces a wide array of medical devices for surgery, orthopedics, and cardiovascular health. In addition to pharmaceuticals, Johnson & Johnson is renowned for its consumer health products, including baby care, skin and hair care, wound care, and over-the-counter pharmaceuticals, with well-recognized brands like Band-Aid, Tylenol, and Neutrogena. Operating globally, the corporation's extensive portfolio and commitment to healthcare innovation make it a pivotal player in the industry, ensuring it remains influential in addressing worldwide health challenges and advancing medical technology.

Exchange NYSE Industry Drug Manufacturers - General Company website ↗

Never miss another JNJ filing

Profitelligence watches EDGAR around the clock and alerts you within seconds.

Set up free alerts